ABBV AbbVie
- 159.610
- -3.320-2.04%
- 160.850
- +1.240+0.78%
AbbVie News
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
This Is What Whales Are Betting On AbbVie
Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV).And retail traders should know.We noticed this today when the positions showed up on publicly available options
2 Billion More Reasons to Buy AbbVie Stock
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)
BaseLaunch Announces a New Partnership With AbbVie
BaseLaunch, the Basel-based biotech venture incubator, today announces that AbbVie has become its newest partner. Through this strategic investment...
These 4 Measures Indicate That AbbVie (NYSE:ABBV) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Teva, Alvotech Launch Biosimilar Against AbbVie's Humira
Express News | NYSE Order Imbalance 57284.0 Shares on Sell Side
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B
Express News | NYSE Order Imbalance 280471.0 Shares on Sell Side
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company.The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve mod
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
5 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent rati
AbbVie Says It Will Present New Data Supporting Leading Gastroenterology Portfolio At 2024 Digestive Disease Week; Company To Present 15 Abstracts, Including Three Oral Presentations, In Crohn's Disease And Ulcerative Colitis
The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually.Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYR
AbbVie Initiated at Overweight by Cantor Fitzgerald
AbbVie Initiated at Overweight by Cantor Fitzgerald
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 21.69% Cantor Fitzgerald → $200 Initiates Coverage On → Overweight 04/29/2024 13.78% Barclays $
Express News | Abbvie Inc : Cantor Fitzgerald Initiates Coverage With Overweight Rating; Price Target $200
ABBV.US (ABBV.US) JAK inhibitors for the treatment of vitiligo are to be included in breakthrough treatment varieties
The upadacitinib tablets submitted by ABBV.US (ABBV.US) are intended to be included as a breakthrough treatment for adolescents and adults aged 12 and above with non-segmental vitiligo.
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory
Express News | NYSE Order Imbalance 174711.0 Shares on Sell Side
Analysis
Price Target
No Data
